ВЛИЯНИЕ МЕНОПАУЗАЛЬНОЙ ГОРМОНАЛЬНОЙ ТЕРАПИИ НА КАЧЕСТВО ЖИЗНИ И МЕТАБОЛИЧЕСКИЙ СТАТУС ЖЕНЩИН ПОСЛЕ ДВУСТОРОННЕЙ ОВАРИОЭКТОМИИ
- Авторы:Шукурова Мунисс Риязовна, Иргашева Севара Уткуровна
- Дата публикации:September 23, 2026
- Тип:Статья
- DOI: 10.64156/mju.9697 Скопировано
- Том / № Выпуска:Том 1 №5 (2026)
Аннотация
Аннотация. Цель — оценить влияние менопаузальной гормональной терапии на симптомы и метаболический статус после двусторонней овариоэктомии. У 78 женщин через 3 и 6 месяцев терапия улучшала клинические показатели.
Ключевые слова: хирургическая менопауза, двусторонняя овариоэктомия, менопаузальная гормональная терапия, качество жизни, метаболический статус, дислипидемия, тревожность.
Annotatsiya. Maqsad — ikki tomonlama ovariektomiyadan keyin menopauzal gormonal terapiyaning simptomlar va metabolik holatga ta’sirini baholash. 78 ayolda 3 va 6 oyda klinik natijalar yaxshilandi.
Kalit so‘zlar: jarrohlik menopauza, ikki tomonlama ovariektomiya, menopauzal gormonal terapiya, hayot sifati, metabolik holat, dislipidemiya, xavotir.
Abstract. Objective: to assess the effect of menopausal hormone therapy on symptoms and metabolic status after bilateral oophorectomy. In 78 women, clinical outcomes improved at 3 and 6 months.
Keywords: surgical menopause, bilateral oophorectomy, menopausal hormone therapy, quality of life, metabolic status, dyslipidemia, anxiety.
References
- 1. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. doi:10.3109/13697137.2015.1129166
- 2. Cho L., Kaunitz A.M., Faubion S.S., Hayes S.N., Lau E.S., Pristera N., Scott N.S., Shufelt C.L., Stuenkel C.A., Wharton G., Lindley K.J. Rethinking menopausal hormone therapy: for whom, what, when, and how long? Circulation. 2023;147(7):597–610. doi:10.1161/CIRCULATIONAHA.122.061559.
- 3. Faubion S.S., Kuhle C.L., Shuster L.T., Rocca W.A. Long-term health consequences of premature or early menopause and considerations for management. Climacteric. 2015;18(4):483–491. doi:10.3109/13697137.2015.1020484.
- 4. Honigberg M.C., Zekavat S.M., Aragam K., Klarin D., Bhatt D.L., Scott N.S., Peloso G.M., Natarajan P. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019;322(24):2411–2421. doi:10.1001/jama.2019.19191.
- 5. Kapoor E., Faubion S.S., Rocca L.G., et al. Trajectories of metabolic parameters after bilateral oophorectomy in premenopausal women. Maturitas. 2022;165:38–46. doi:10.1016/j.maturitas.2022.07.005.
- 6. Kapoor E., Kling J.M., Lobo A.S., Faubion S.S. Menopausal hormone therapy in women with medical conditions. Best Practice & Research Clinical Endocrinology & Metabolism. 2021;35(6):101578. doi:10.1016/j.beem.2021.101578.
- 7. Kaunitz A.M., Kapoor E., Faubion S.S. Treatment of women after bilateral salpingo-oophorectomy performed prior to natural menopause. JAMA. 2021;326(14):1429–1430. doi:10.1001/jama.2021.3305.
- 8. Kotsopoulos J., Hall E., Finch A., et al. Changes in bone mineral density after prophylactic bilateral salpingo-oophorectomy in carriers of a BRCA mutation. JAMA Network Open. 2019;2(8):e198420. doi:10.1001/jamanetworkopen.2019.8420.
- 9. Lambrinoudaki I., Paschou S.A., Lumsden M.A., et al. Menopause, wellbeing and health: a care pathway from the European Menopause and Andropause Society. Maturitas. 2022;163:1–14. doi:10.1016/j.maturitas.2022.04.008.
- 10. Mendoza N., Ramírez I., de la Viuda E., et al. Eligibility criteria for menopausal hormone therapy: a position statement from a consortium of scientific societies for the use of menopausal hormone therapy in women with medical conditions. Maturitas. 2022;166:65–85. doi:10.1016/j.maturitas.2022.08.008.
- 11. The 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028.
- 12. Panay N., Anderson R.A., Nappi R.E., et al. Evidence-based guideline: premature ovarian insufficiency. Human Reproduction Open. 2024;2024(4):hoae065. doi:10.1093/hropen/hoae065.
- 13. Rocca W.A., Gazzuola Rocca L., Smith C.Y., et al. Accelerated accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study. Mayo Clinic Proceedings. 2016;91(11):1577–1589. doi:10.1016/j.mayocp.2016.08.002.
- 14. Sullivan S.D., Sarrel P.M., Nelson L.M. Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertility and Sterility. 2016;106(7):1580–1587. doi:10.1016/j.fertnstert.2016.09.018.
- 15. Webber L., Davies M., Anderson R., Bartlett J., Braat D., Cartwright B., et al. Hormone replacement therapy for women with premature ovarian insufficiency: a comprehensive review. Human Reproduction Open. 2017;2017(2):hox007. doi:10.1093/hropen/hox007